Blog Read the latest perspectives from our team of subject matter experts and others How to Build a Scalable Diversity StrategyPut simply – in 2022, clinical trial diversity, equity and inclusion (DEI) was top of mind for the pharma and biotech industries, across all phases of drug and device… Continue reading → Read the article Post Topics:Commercialization Diversity & Inclusion Drug Development KOL Engagement Medical Devices Provider Data Research Post Industries:Commercialization Medical Devices Payors Pharmaceutical & Biotechnology Provider Data Research CommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchH1 Raises Series CToday we announced our Series C of $100 million led by Altimeter and participation from new investors including Goldman Sachs Asset Management and Flex Capital. It also includes the support… Continue reading → Read the article Drug DevelopmentReal World Data: Sources and Effective EvaluationHelp you understand what real world data (RWD) is and how it is used. Discuss the many sources of RWD and how tracking and measuring RWD can be challenging.… Continue reading → Read the article KOL EngagementHow Physicians Are Compensated by Life Sciences CompaniesIt’s no secret that compensation for physicians consulting at pharmaceutical, device and life sciences firms is often much higher than what’s on the table at hospitals and university-affiliated medical centers.… Continue reading → Read the article CommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchFormer Dropbox CIO Joins Board of Healthcare Data Startup H1Board member Sylvie Veilleux (Salesforce, Dropbox), CFO Karen Moran (Alteryx, Domo) and CDO Mayur Thakur (Goldman Sachs, Google) bring decades of experience and add bench strength as H1 expands.… Continue reading → Read the article Diversity & InclusionDrug DevelopmentThe Post-Pandemic Future of Clinical TrialsIn a post-COVID world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow… Continue reading → Read the article CommercializationDiversity & InclusionDrug DevelopmentWhy Diversity Matters for PharmaDiversity matters for pharma because inclusion, trust and equity matter for pharma. When developing therapies and medications, pharmaceutical and life sciences companies are tasked with designing products for a… Continue reading → Read the article«‹2345678›»
